Status:
COMPLETED
18F-FET PET/CT in the Management of Glioma
Lead Sponsor:
Buddhist Tzu Chi General Hospital
Conditions:
Glioma
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
O-(2-\[18F\]-fluoroethyl)-L-tyrosine (FET) is a tracer for positron emission tomography (PET). The Response Assessment in Neuro-Oncology (RANO) working group has officially recommended 18F-FET PET in ...
Detailed Description
Study background: O-(2-\[18F\]-fluoroethyl)-L-tyrosine (FET) is a tracer for positron emission tomography (PET). The Response Assessment in Neuro-Oncology (RANO) working group has officially recommen...
Eligibility Criteria
Inclusion
- Patients with primary or recurrent brain tumors confirmed by pathological examination or imaging studies.
- The ability to provide written informed consent and receive the scheduled scan.
Exclusion
- Woman with pregnancy or during lactation.
- Unsuitable for PET scans, such as those with claustrophobia or inability to lie flat.
- Unable to sign the informed consent form.
- Patients with a second primary tumor.
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2023
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT06563024
Start Date
August 1 2020
End Date
December 30 2023
Last Update
August 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hualien Tzu Chi Hospital
Hualien City, Taiwan